Congestive heart failure is a rare event in patients receiving imatinib therapy.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaPharmacology and rationale for imatinib in the treatment of sclerodermaRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsMitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibFirst-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study.Practical management of patients with chronic myeloid leukemia.Cardiovascular disease in adult survivors of childhood cancer.Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaChronic myelogenous leukemia: treatment and monitoring.Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trialRare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate.Prior exposure to imatinib does not impact outcome of allogeneic hematopoietic transplantation for chronic myeloid leukemia patients: a single-center experience in chinaManaging chemotherapy-related cardiotoxicity in survivors of childhood cancers.Gastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts.Clinical cardiac safety profile of nilotinib.Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy.Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.Imatinib mesylate in the treatment of hematologic malignancies.A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.Update in pulmonary arterial hypertension 2007.Imatinib mesylate for the treatment of chronic myeloid leukemia.Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problemTherapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.Targeted therapy: comprehensive review.Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group studyCardiovascular effects of noncardiovascular drugs.Leads for the treatment of pulmonary hypertension.Safety profile of new anticancer drugs.Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.Role of allo-SCT for CML in 2010.The management of acute pulmonary arterial hypertension.Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
P2860
Q26749324-A3726A0E-FCA3-4E8E-9C9F-D5362299B850Q26825153-7047EBCF-2A94-4E61-8DE4-0B9A8FD44613Q28087776-9F8EB54B-1C43-40F8-88F0-15A542306A03Q28296128-5AE85EEA-5498-4302-9753-D05793FD5000Q30492863-1E23AB45-AD16-4AFC-875C-63AE13FD6278Q30891587-1A3D9E27-DD54-4A90-B03E-DD25740A8534Q33391185-44C40176-6CA3-4C4A-A6A1-218CC9560A93Q33392977-4A755EEE-A9CB-433F-A7F2-AC095AC19D1EQ33401360-FC3F954D-A7E5-4442-8A43-E551600BA8EAQ33412429-0DE379D2-7295-4FFC-9E97-0B1A2B6EAFDFQ33849146-E443727F-2722-4DB5-BDAD-6CF7CF3DEFE3Q34042984-D20F01BC-EE04-4F41-9CF1-9E0720C21DA8Q34443523-A97B1028-DDAC-4692-A35F-0E425A39C587Q34522789-F9A78AD5-974E-4156-8784-7EF79210FF4CQ34617628-6F73A5BE-15FC-4C12-BD5D-B60FF2B115A7Q34906164-54B924F1-09C5-43F7-94ED-7AD3468D76CDQ35012761-515ED566-53EA-49CC-94C3-1790E9F251E7Q35480678-C4D328B5-FCCC-49A8-91C0-4A44D538C64AQ35562745-C3594547-83C0-4EC7-8ED5-0DDA252D2C38Q35679349-33995CEB-5D87-4411-A0DD-525D30B435EAQ36006389-17A34A3E-7F77-4627-9557-5BF8BAB84E37Q36316309-2A690AE7-5534-4441-9A09-BBEE14438D8AQ36676062-6F7B5050-61D9-44FB-863B-5D18CC965B33Q36891574-FDBB30EB-C84E-448A-9A5E-68EA959FA98AQ36960525-57710559-8D53-485C-B850-65E8FB1C66E0Q37052843-3D14EB1C-ED22-4B89-BA23-7F6F26323EEAQ37100702-306F0103-B044-4D9D-BC71-ABF0150BD490Q37183434-CBB55319-5874-49E4-95AC-3A1EAB0E9486Q37203741-D3C65821-923B-4C06-B751-98A26F5051B3Q37212411-EE263C84-27C0-4F78-BDE7-3EF1C9E019ACQ37271941-E687918E-736C-403C-93ED-0F9A240E5070Q37396743-04AE3192-C03B-4B6E-AA6D-607264B86ECBQ37412290-96CFA5E4-0B4C-4D54-B360-7BDA3655A07AQ37413163-37AE976F-271E-48E1-B493-6955F4652912Q37481343-F60E6692-61C7-4948-8CFE-DF4CD2C9838BQ37696502-47D93DC1-5A7C-4AAF-8299-CFEDA936050EQ37763106-8B42498F-0D91-40AA-B466-E9A681369B1AQ37763493-C09FF84E-93B0-47AE-BFD3-A96C26151C1FQ37766261-16CE01F4-1605-415B-BF22-DEB9F5535040Q37791429-4D805341-CFAB-4FB8-B892-387186DAB433
P2860
Congestive heart failure is a rare event in patients receiving imatinib therapy.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Congestive heart failure is a rare event in patients receiving imatinib therapy.
@ast
Congestive heart failure is a rare event in patients receiving imatinib therapy.
@en
Congestive heart failure is a rare event in patients receiving imatinib therapy.
@nl
type
label
Congestive heart failure is a rare event in patients receiving imatinib therapy.
@ast
Congestive heart failure is a rare event in patients receiving imatinib therapy.
@en
Congestive heart failure is a rare event in patients receiving imatinib therapy.
@nl
prefLabel
Congestive heart failure is a rare event in patients receiving imatinib therapy.
@ast
Congestive heart failure is a rare event in patients receiving imatinib therapy.
@en
Congestive heart failure is a rare event in patients receiving imatinib therapy.
@nl
P1433
P1476
Congestive heart failure is a rare event in patients receiving imatinib therapy.
@en
P2093
Ehab Atallah
Jean-Bernard Durand
P304
P356
10.1182/BLOOD-2007-01-070144
P407
P577
2007-04-20T00:00:00Z